From ASCVD Pooled Cohort Equations to PREVENT: Rethinking Cardiovascular Risk

n this episode of MDAware: Upgrading Clinical Judgment, Dr. Shazia Siddique talks with Dr. Sadiya Khan and Dr. Donald Lloyd-Jones about the PREVENT equations and why they're replacing the atherosclerotic cardiovascular disease (ASCVD) pooled cohort equations (PCEs) that have guided cardiovascular risk assessment for over a decade. A conversation about what changes when a risk tool expands beyond a single disease outcome, and why the same patient can get two different risk numbers depending on which calculator a clinician reaches for, and how this shapes the treatment conversation.

Dr. Khan is a preventive cardiologist at Northwestern who led the development and validation of the PREVENT equations. Dr. Lloyd-Jones directs the Framingham Heart Study and was a lead voice on risk assessment going back to the original pooled cohort equations. Together they trace the full arc: from the 1998 Framingham risk equations, built almost entirely on a European ancestry population, to the 2013 pooled cohort equations, to PREVENT itself, which now accounts for coronary heart disease, stroke, and heart failure in a single model, drawing on data from more than six million individuals.

Dr. Khan and Dr. Lloyd-Jones also walk through one of the more consequential decisions behind PREVENT: removing race as a variable in the equations, and why that decision didn't come at the cost of accuracy across different populations. From there, the conversation moves into how PREVENT is already being applied in the 2025 blood pressure guidelines, the CPR framework (calculate, personalize, reclassify) for translating a risk score into an actual treatment conversation, and what role tools like coronary artery calcium scoring play when the picture still isn't clear.

What You'll Learn

• Why coronary heart disease alone was an inadequate endpoint for risk prediction, and how leaving stroke and heart failure out of the equation left real risk on the table, particularly for women and Black Americans
• Why and how PREVENT drops race as a predictor in favor of directly measured risk factors
• What CPR (calculate, personalize, reclassify) means in practice
• How the new 2025 blood pressure guidelines arrived at the PREVENT CVD 7.5% threshold
• Why a risk score can tell you where a patient stands today, but can't calculate the benefit of a hypothetical intervention, and why that distinction matters at the bedside

Links & Resources

MDCalc: mdcalc.com

Follow MDCalc on LinkedIn: linkedin.com/company/mdcalc

Follow MDCalc on X/Twitter: @MDCalc